Barry Cohen

Barry Cohen

Barry Cohen has nearly 30 years in communications and marketing, the majority in senior positions at three large international health care companies – Abbott Laboratories, Warner-Lambert (now part of Pfizer) and Bayer, Inc.

At Abbott, Cohen was a member of the company’s investor relations team, responsible for preparing all financial analyst presentations. He also oversaw the company’s award-winning annual and quarterly reports and was responsible for both the company’s investor seminar and annual shareholders’ meeting.

After relocating to Arizona, Cohen served as editor of M.D. News, a magazine for Phoenix-area physicians. Later he was a reporter for a weekly newspaper in a north Phoenix, where he specialized in business articles and profiles of local publicly traded companies.

To further his knowledge and understanding of financial markets, Cohen earned a series 7 broker’s license and was employed at Charles Schwab as a registered representative.  He returned to the communications field with CPRi Communications, where he wrote numerous case studies and bylined articles for the company’s clients in the health care information technology industry. Later, he worked for a Scottsdale, Ariz.-based investment bank preparing profiles of companies being offered for sale.

Recent Articles

Onyx Pharma May See Suitors Lining Up

The company's current and future drugs are likely attractive to larger companies faced with slowing growth.

Ranbaxy Closes In on FDA Approval for Generic Lipitor

Ranbaxy could sell $650 million worth of the drug in its first 180 days. But Pfizer is battling hard to keep branded Lipitor alive.

Blood-Thinner Drug Race Is Still Wide Open

The major pharmaceutical companies are hoping to supply the definitive treatments, but the medical community hasn't yet declared a winner.

Merck CEO Pledges Drug Pipeline Will Yield Results in Both Short and Long Term

Merck CEO Kenneth Frazier acknowledges company's lagging stock, touts potential of numerous drugs in late development stages.

Pfizer’s Latest Gambit for Keeping Lipitor Alive

Like a vampire refusing to die, Lipitor keeps on going. Now, PFE has a deal to sell the cholesterol-lowering drug directly to patients at generic cost.

Gilead’s Giant Gamble in Buying Pharmasset

The $11B price tag raises the stakes big-time, and critics say Gilead is overpaying to get Pharmasset's promising hepatitis C treatment.

Stocks to Watch on Cancer Vaccines’ Huge Financial Potential

These companies are making progress on new therapeutic cancer vaccines -- and success for any one of them could be huge for investors.

Big Pharma’s Emerging Markets Foray Hits Roadblocks

Companies are finding plans for global expansion aren't without hiccups.

Bristol-Myers, AstraZeneca Diabetes Drug Gets New Hope

Cleveland Clinic's positive review revitalizes Bristol-Myers, AstraZeneca's dapagliflozin, an experimental drug taking on a growing diabetes management market.

Sanofi Relies on Shopping to Offset Patent Losses on Key Drugs

French drug giant Sanofi (SNY) is counting on mergers and acquisitions to restore profit growth amid a slew of patent expirations.